The Sickle Cell Clinical Trials Network: One Year In
The Hematologist Editor-in-Chief, Dr. Laura Michaelis, spoke with Drs. Charles Abrams and Sophie Lanzkron about a groundbreaking ASH initiative started approximate
RNA Isoforms, Innate Immunity, and Leukemogenesis: IRAK4 As a Novel Therapeutic Target in MDS/AML
Drs. Brierley and Mead discuss a study that identified a poor-prognosis subtype of MDS/AML defined by the accumulation of certain mRNA isoform changes in innate immune path
Dr. Gary Lyman examines the safety and efficacy of biosimilars approved by the U.S. Food and Drug Administration.
Dr. Saad Usmani discusses "Empires of the Indus" by Alice Albinia, a nonfiction book about the author's travels along the river.
Drs. Kristen O'Dwyer and Wendy Stock discuss they CALGB 10403 Trial, which tests the efficacy and feasibility of a pediatric regimen for AYAs with newly diagnosed B- or T-lineage Philadelphia chromosome-negative ALL.
May/June 2019Volume 16, Issue 3
View all Features articles
View all Diffusion articles
Dr. Silverstein discusses the Society's efforts to help hematologists become effective teachers and preachers of continuous quality improvement.
View all president's column articles
View all Ask the Hematologist articles
View all Clinical Trials Corner articles
View all Mini Review articles
ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.
ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.
In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.
In 2018, ASH commented on numerous rules and regulations proposed by the Centers for Medicare and Medicaid Services (CMS), which impact physician payment. ASH is actively involved in various advisory committees and also continues to engage with lawmakers on Capitol Hill.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology